Asia-Pacific Diagnostic Tests Market – Industry Trends and Forecast to 2030

Asia-Pacific Diagnostic Tests Market, By Type (Glucose Test, Infectious Diseases Test, Cytology Test, CBC Test, Blood Culture Test, Syphilis Test, Urea Test, C-Reactive Protein Test, Antigen Test, HBA1C Test, Pregnancy Test, Lipid Profile Test, Electrolytes Test, Liver Function Test, Stool Helicobacter Pylori Test, Calcium Test, Crossmatch Test, Thyroid Function Test, Stool Microscopy Test, Urine Microscopy Test, Unit Packed RBCS Test, ESR Test and Others Test), Solutions (Services and Products), Technology (Immunoassay-Based, PCR-Based, Next Gene Sequencing, Spectroscopy-Based, Chromatography-Based, Microfluidics, Substrate Technology and Others), Mode of Testing (Prescription-Based Testing and OTC Testing), Approach (Molecular Diagnostic Instrument, In-Vitro Diagnostic Instrument and Point Of Care Testing Instrument), Sample Type (Urine, Saliva, Blood, Hair, Sweat and Others), Application (Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Odontology and Others), Testing Type (Biochemistry, Haematology, Microbiology, Histopathology and Others), Age (Pediatric, Adult and Geriatric), End User (Hospitals, Diagnostic Center, Research Labs and Institutes, Research Institute, Homecare, Blood Banks, Specialty Clinics, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tenders, Retail Sales and Online Sales) – Industry Trends and Forecast to 2030.

Asia-Pacific Diagnostic Tests Market Analysis and Size

According to the World Health Organization's (WHO), chronic diseases will account for approximately 41 million deaths annually by April 2021, accounting for 71% of all fatalities worldwide. As a result, diagnostic tests have proven useful in the management of chronic illness conditions, as well as in disease prevention, detection, and diagnosis. By identifying individual risk factors and early warning indicators, clinical diagnostics open up new avenues for early prevention and intervention. As a result, the overall market is expected to grow as the prevalence of chronic illnesses rises.

Data Bridge Market Research analyses that the diagnostic tests market, which was USD 160,573.05 million in 2022, is expected to reach USD 351,784.56 million by 2030, at a CAGR of 10.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Diagnostic Tests Market Scope and Segmentation

Market Definition

Diagnostic tests are medical tests that are used to aid in the detection or diagnosis of any disease. These tests are critical in disease control, surveillance, and prevention. These tests help improve patient care, consumer safety, and healthcare spending. A diagnostic test is one that is used to determine the cause of a condition. A diagnostic test used as part of a medical examination may be used to determine the cause of symptoms or to identify a disease. A diagnostic test can be used to identify specific strengths and weaknesses when used for other purposes.

Asia-Pacific Diagnostic Tests Market Dynamics

Drivers

• Growing incidences of infectious and chronic diseases

Infectious diseases and chronic conditions are weighing heavily on the world's population. Microorganisms cause infectious diseases such as diphtheria, ebola, flu, hepatitis, HIV/AIDS, HPV, tuberculosis, and others, and sudden outbreaks such as dengue, Zika virus, COVID-19, and Swine flu drive international demand for clinical diagnostic tests. Furthermore, chronic disorders such as various types of cancers, diabetes, cardiovascular diseases, obesity, and many others are increasing the demand for clinical diagnostics.

• Rising clinical diagnostic tests

Clinical diagnostic tests are the most precise methods for identifying and characterizing microorganisms. A practical test must be accurate, quick, and capable of determining the level of infection. Better testing determines the organism's strain and drug susceptibility more quickly, reducing the time it takes to find the right antibiotic. According to a World Health Organization (WHO) report published in 2018, tuberculosis (T.B.) was one of the top ten causes of death worldwide. This is likely to be a significant market growth factor. The availability and accessibility to better diagnostic procedures are primarily responsible for the high incidence of cancer cases in living standards. Clinical cancer diagnostics equipment is widely used in these procedures, so demand of diagnostic tests are rise during the forecast period.

Opportunities

• Growing demand for advanced diagnostic solutions

Clinical diagnostics are used to manage the health of patients. It allows for the detection of diseases at an earlier stage and aids in the progression of illnesses. Furthermore, it may help infected people avoid long-term consequences, raising public awareness of the importance of clinical diagnosis. Increased healthcare spending and health awareness promote market expansion. The demand for clinical diagnostic kits is expected to rise during the forecast period as people become more concerned about the risk of disease transmission from infected patients. Diagnostic testing can be performed with the help of either services or tools and supplies. This feature will most likely improve patient convenience, which will benefit the market.

Restraints/Challenges

• Non-affordability for diagnostics tests

Pricing pressure from reimbursement cuts and budget constraints, as well as stringent regulatory policies, are expected to hamper the market growth. In addition, the diagnostic tests market is expected to be challenged by a lack of alignment with definitive central lab methods and inadequate adoption of POC devices in professional settings during the forecast period of 2023-2030.

This diagnostic tests market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the diagnostic tests market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Diagnostic Tests Market

COVID-19 had a negative impact on the diagnostic tests market because lab testing has increased, causing demand to increase even faster to keep up with suspected COVID-19 cases. According to the Atlantic Monthly Group, the COVID-19 test count increased dramatically worldwide, from 760,441 tests in September 2020 to 964,792 new tests in October 2020. As a result, the increasing number of tests due to the ongoing increase in patients and government financing is expected to drive demand for COVID-19 test kits and fuel the overall market's exponential growth.

Recent developments

• In March 2020, Siemens Healthcare GmbH officially announced the RAPIDPoint 500e Blood Gas Analyzer launch, which expanded the company's product portfolio and is also used in COVID-19 efforts. This assists in increasing revenue from the line.
• In March 2020, Siemens Healthcare GmbH and the Marienhaus Hospital Group announced a ten-year partnership. This collaboration will benefit the company in the long run in diagnostics. This agreement will also improve the company's financials.

Asia-Pacific Diagnostic Tests Market Scope

The diagnostic tests market is segmented on the basis of type, solution, technology, mode of testing, approach, sample type, application, testing type, age, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Glucose Test
• Infectious Diseases Test
• Cytology Test
• CBC Test
• Blood Culture Test
• Syphilis Test
• Urea Test
• C-Reactive Protein Test
• Antigen Test
• HBA1C Test
• Pregnancy Test
• Lipid Profile Test
• Electrolytes Test
• Liver Function Test
• Stool Helicobacter Pylori Test
• Calcium Test, Crossmatch Test
• Thyroid Function Test
• Stool Microscopy Test
• Urine Microscopy Test
• Unit Packed Rbcs Test
• ESR Test And Others Test

Solutions

• Services
• Products

Technology

• Immunoassay-Based
• PCR-Based
• Next Gene Sequencing
• Spectroscopy-Based
• Chromatography-Based
• Microfluidics
• Substrate Technology
• Others

Mode of Testing

• Prescription-Based Testing
• OTC Testing

Approach

• Molecular Diagnostic Instrument
• In-Vitro Diagnostic Instrument
• Point of Care Testing Instrument

Sample Type

• Urine
• Saliva
• Blood
• Hair
• Sweat
• Others

Application

• Cardiology
• Oncology
• Neurology
• Orthopedics
• Gastroenterology
• Gynecology
• Odontology
• Others

Testing Type

• Biochemistry
• Hematology
• Microbiology
• Histopathology
• Others

Age

• Pediatric
• Adult
• Geriatric

End User

• Hospitals, Diagnostic Center
• Research Labs and Institutes
• Research Institute
• Homecare
• Blood Banks
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Distribution Channel

• Direct Tenders
• Retail Sales
• Online Sales

Asia-Pacific Diagnostic Tests Market Regional Analysis/Insights

The diagnostic tests market is analysed and market size insights and trends are provided by country, type, solution, technology, mode of testing, approach, sample type, application, testing type, age, end user and distribution channel as referenced above.

The countries covered in the diagnostic tests market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)

The Asia-Pacific region is expected to grow fastest from 2023 to 2030, owing to an increased demand for personalized medicine for specific tumors and cancer patients and the widespread use of diagnostic tests in preclinical research. China is leading the growth of the Asia-Pacific market, because of strategic initiatives by the government and private sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Diagnostic Tests Market Share Analysis

The diagnostic tests market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diagnostic tests market.

Some of the major players operating in the diagnostic tests market are:

• F-Hoffman La-Rcohe Ltd. (Switzerland)
• ABBOTT (U.S.)
• Danaher (U.S.)
• B.D. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• ACON Laboratories Inc. (U.S.)
• Hemosure, Inc. (U.S.)
• MicroGen Diagnostics (U.S.)
• QIAGEN (Germany)
• Grifols, S.A (Spain)
• BODITECH MED INC. (South Korea)
• Chembio Diagnostic Systems, Inc. (U.S.)
• Nanoentek (South Korea)
• DiaSorin S.p.A. (Italy)
• Bio-Rad Laboratories, Inc. (U.S.)
• BIOMEDOMICS INC (U.S.)
• EKF Diagnostics Holdings plc (U.K.)
• Siemens Healthcare GmbH (Germany)
• PerkinElmer Inc. (U.S.)
• BIOMÉRIEUX (France)
• ARKRAY USA, Inc. (U.S.)
• Biohit Oyj (Finland)
• Germaine Laboratories, Inc. (U.S.)
• Quidel Corporation (U.S.)
• Illumina, Inc. (U.S.)
• Lamdagen Corporation (U.S.)
• LifeSign LLC. (U.S.)
• Medixbiochemica (Finland)
• Nova Biomedical (U.S.)
• Ortho Clinical Diagnostics (U.S.)
• Sannuo Biosensing Co., Ltd. (U.S.)
• STRECK (U.S.)
• Sysmex Corporation (Japan)